Compare Mesoblast Limited (MESO) vs VanEck Semiconductor ETF (SMH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs VanEck Semiconductor ETF — how do they compare? Mesoblast Limited trades at $16.08 (market cap $2.17B), while VanEck Semiconductor ETF trades at $577.9. The key difference: VanEck Semiconductor ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MESO | SMH | |
|---|---|---|
Market Cap | $2.17B | — |
Sector | Technology | — |
52-Week High | $20.96 | $668.91 |
52-Week Low | $12.88 | $283.95 |
Enterprise Value | $2.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
SMH trades at $558.83, up 0.54% with a bearish technical signal from moving averages. The ETF faces sector volatility amid AI-driven selloffs, with key support at $547 and resistance at $566. Recent news highlights institutional accumulation by Assetmark Inc. while chip stocks correct from highs.
Outlook hinges on semiconductor cycle resilience; risks include crowded trades and geopolitical tensions. Diversification within SMH’s top-heavy portfolio may cushion volatility, but investor caution is warranted given bearish momentum and sector reset warnings from BofA (Market Watch, July 17, 2026).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About VanEck Semiconductor ETF
The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →
